OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Marshall on Physician Burnout in Oncology

January 31st 2020

John L. Marshall, MD, discusses physician burnout in oncology.

Dr. Kalinsky on Clinical Impact of Atezolizumab Combo in TNBC

January 31st 2020

Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.

Dr. Liebman on Toxicities of BRAF Inhibitors in Melanoma

January 31st 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

Dr. Kreitman on the Use of Moxetumomab Pasudotox in Hairy Cell Leukemia

January 31st 2020

Robert J. Kreitman, MD, senior investigator and head of the Clinical Immunotherapy Section in the Laboratory of Molecular Biology at the National Cancer Institute, discusses the use of moxetumomab pasudotox-tdfk (Lumoxiti) in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL).

Dr. Allan on the Use of Vecabrutinib Therapy in B-Cell Malignancies

January 31st 2020

John N. Allan, MD, assistant attending physician at NewYork-Presbyterian Hospital and assistant professor of medicine, Weill Cornell Medical College, Cornell University, discusses the use of vecabrutinib (SNS-062) therapy in patients with B-cell malignancies.

Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL

January 31st 2020

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).

Dr. Ghobrial on Triplet Regimen in Smoldering Myeloma

January 31st 2020

Irene Ghobrial, MD, discusses the combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone in smoldering multiple myeloma.

Dr. Braun on Evolution of Immunotherapy in Advanced Renal Cell Carcinoma

January 30th 2020

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung Cancer

January 30th 2020

Justin F. Gainor, MD, discusses a neoadjuvant use of biomarkers in nonmetastatic lung cancer.

The Importance of Combination Immune Therapy in Orthotopic Murine Glioblastoma

January 30th 2020

Connor Liu, medical student, Washington University School of Medicine, discusses the importance of combination immunotherapy in orthotopic murine glioblastoma.

Dr. Paner on HORIZON Trial in Multiple Myeloma

January 30th 2020

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

January 30th 2020

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Bryce on Ongoing Research Regarding CDK12 Alterations in Prostate Cancer

January 30th 2020

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Dr. Shinohara on Toxicities of Stereotactic Body Radiotherapy in Prostate Cancer

January 30th 2020

Eric Shinohara, MD, MSCI, discusses the toxicities associated with stereotactic body radiotherapy in prostate cancer.

Dr. Oh on the ENZAMET Trial in mHSPC

January 30th 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Randall of Tumor Sequencing Research in Sarcomas

January 30th 2020

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Dr. Hudson on the Rise of Liquid Biopsies in Lung Cancer

January 30th 2020

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Dr. Polsky on the Exploration of Blood-Based Biomarkers in Melanoma

January 30th 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Dr. Coleman on the Use of Veliparib in Ovarian Cancer

January 29th 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the use of veliparib in ovarian cancer.

Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer

January 29th 2020

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.